March Journal Articles about Hepatitis C

March Journal Articles about Hepatitis CThe following highlights a variety of journal articles, published in March 2016, about hepatitis C and hepatitis C treatments.

Clinical Transplant (March 2016)

Summary: This trial tested the hep C treatment sofosbuvir / simeprevir on patients who have had liver transplants. 88% of patients achieved sustained virologic response/”cure”.

CMAJ (March 2016)

Summary: With as many as 1700 eligible hep C patients in Canadian correctional facilities, Correctional Service of Canada (CSC) has decided to add only another 50 patients to its current target of 240 in treatment yearly.

 Hepatology (March 2016)

Summary: Galexos (simeprevir) + Sovaldi (sofosbuvir) for 12 weeks is effective when treating those with hep C genotype 1, non-cirrhotic patients, including those with Q80K (97% with 12 weeks of treatment; 83% with 8 weeks).

Summary: This “real-world” study evaluated treatment for patients who’s previous treatment failed. After taking daclatasvir (DCV) plus pegylated interferon and ribavirin (PR), with or without asunaprevir, and failing to achieve SVR/cure, trial subjects were retreated with  sofosbuvir and simeprevir for 12 weeks. This retreatment was successful and cured all but 2 patients. However, the study showed that longer treatments with ribavirin as well may be required.

Summary: This trial indicated that the treatment daclatasvir, sofosbuvir, and ribavirin, a combination for all hep C genotypes, was safe for and well tolerated by patients with advanced cirrhosis or virus recurrence after a liver transplantation.

Summary: This trial concluded that the treatment daclatasvir and sofosbuvir with ribavirin was successful (90% overall, 86% in patients with cirrhosis) after 12 or 16 weeks of treatment for hep C genotype 3 patients with advanced liver disease, regardless of their past hep C treatment experiences.

Journal of Hepatology (March 2016)

Summary: This study set out to assess patient-reported  general health and emotional well-being outcomes of the hep C treatment sofosbuvir / velpatasvir when compared with a placebo. The results showed that after only 4 weeks on  sofosbuvir / velpatasvir, patients experienced improvements in general health and emotional well-being. Those taking the placebo reported no improvement.

Transplant Infectious Disease (March 2016)

Summary: Hepatitis C is hard on patients post liver transplantation. This study looked at Harvoni (sofosbuvir/ ledipasvir) on those post liver transplant and found that the treatment is safe, highly effective, and well tolerated by those patients post liver transplantation.